Safety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foals

In 2011, following severe flooding in Eastern Australia, an unprecedented epidemic of equine encephalitis occurred in South-Eastern Australia, caused by Murray Valley encephalitis virus (MVEV) and a new variant strain of Kunjin virus, a subtype of West Nile virus (WNV(KUN)). This prompted us to asse...

Descripción completa

Detalles Bibliográficos
Autores principales: Bielefeldt-Ohmann, Helle, Prow, Natalie A, Wang, Wenqi, Tan, Cindy SE, Coyle, Mitchell, Douma, Alysha, Hobson-Peters, Jody, Kidd, Lisa, Hall, Roy A, Petrovsky, Nikolai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268807/
https://www.ncbi.nlm.nih.gov/pubmed/25516480
http://dx.doi.org/10.1186/s13567-014-0130-7
_version_ 1782349292105629696
author Bielefeldt-Ohmann, Helle
Prow, Natalie A
Wang, Wenqi
Tan, Cindy SE
Coyle, Mitchell
Douma, Alysha
Hobson-Peters, Jody
Kidd, Lisa
Hall, Roy A
Petrovsky, Nikolai
author_facet Bielefeldt-Ohmann, Helle
Prow, Natalie A
Wang, Wenqi
Tan, Cindy SE
Coyle, Mitchell
Douma, Alysha
Hobson-Peters, Jody
Kidd, Lisa
Hall, Roy A
Petrovsky, Nikolai
author_sort Bielefeldt-Ohmann, Helle
collection PubMed
description In 2011, following severe flooding in Eastern Australia, an unprecedented epidemic of equine encephalitis occurred in South-Eastern Australia, caused by Murray Valley encephalitis virus (MVEV) and a new variant strain of Kunjin virus, a subtype of West Nile virus (WNV(KUN)). This prompted us to assess whether a delta inulin-adjuvanted, inactivated cell culture-derived Japanese encephalitis virus (JEV) vaccine (JE-ADVAX™) could be used in horses, including pregnant mares and foals, to not only induce immunity to JEV, but also elicit cross-protective antibodies against MVEV and WNV(KUN). Foals, 74–152 days old, received two injections of JE-ADVAX™. The vaccine was safe and well-tolerated and induced a strong JEV-neutralizing antibody response in all foals. MVEV and WNV(KUN) antibody cross-reactivity was seen in 33% and 42% of the immunized foals, respectively. JE-ADVAX™ was also safe and well-tolerated in pregnant mares and induced high JEV-neutralizing titers. The neutralizing activity was passively transferred to their foals via colostrum. Foals that acquired passive immunity to JEV via maternal antibodies then were immunized with JE-ADVAX™ at 36–83 days of age, showed evidence of maternal antibody interference with low peak antibody titers post-immunization when compared to immunized foals of JEV-naïve dams. Nevertheless, when given a single JE-ADVAX™ booster immunization as yearlings, these animals developed a rapid and robust JEV-neutralizing antibody response, indicating that they were successfully primed to JEV when immunized as foals, despite the presence of maternal antibodies. Overall, JE-ADVAX™ appears safe and well-tolerated in pregnant mares and young foals and induces protective levels of JEV neutralizing antibodies with partial cross-neutralization of MVEV and WNV(KUN).
format Online
Article
Text
id pubmed-4268807
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42688072014-12-17 Safety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foals Bielefeldt-Ohmann, Helle Prow, Natalie A Wang, Wenqi Tan, Cindy SE Coyle, Mitchell Douma, Alysha Hobson-Peters, Jody Kidd, Lisa Hall, Roy A Petrovsky, Nikolai Vet Res Research In 2011, following severe flooding in Eastern Australia, an unprecedented epidemic of equine encephalitis occurred in South-Eastern Australia, caused by Murray Valley encephalitis virus (MVEV) and a new variant strain of Kunjin virus, a subtype of West Nile virus (WNV(KUN)). This prompted us to assess whether a delta inulin-adjuvanted, inactivated cell culture-derived Japanese encephalitis virus (JEV) vaccine (JE-ADVAX™) could be used in horses, including pregnant mares and foals, to not only induce immunity to JEV, but also elicit cross-protective antibodies against MVEV and WNV(KUN). Foals, 74–152 days old, received two injections of JE-ADVAX™. The vaccine was safe and well-tolerated and induced a strong JEV-neutralizing antibody response in all foals. MVEV and WNV(KUN) antibody cross-reactivity was seen in 33% and 42% of the immunized foals, respectively. JE-ADVAX™ was also safe and well-tolerated in pregnant mares and induced high JEV-neutralizing titers. The neutralizing activity was passively transferred to their foals via colostrum. Foals that acquired passive immunity to JEV via maternal antibodies then were immunized with JE-ADVAX™ at 36–83 days of age, showed evidence of maternal antibody interference with low peak antibody titers post-immunization when compared to immunized foals of JEV-naïve dams. Nevertheless, when given a single JE-ADVAX™ booster immunization as yearlings, these animals developed a rapid and robust JEV-neutralizing antibody response, indicating that they were successfully primed to JEV when immunized as foals, despite the presence of maternal antibodies. Overall, JE-ADVAX™ appears safe and well-tolerated in pregnant mares and young foals and induces protective levels of JEV neutralizing antibodies with partial cross-neutralization of MVEV and WNV(KUN). BioMed Central 2014-12-17 2014 /pmc/articles/PMC4268807/ /pubmed/25516480 http://dx.doi.org/10.1186/s13567-014-0130-7 Text en © Bielefeldt-Ohmann et al.; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Bielefeldt-Ohmann, Helle
Prow, Natalie A
Wang, Wenqi
Tan, Cindy SE
Coyle, Mitchell
Douma, Alysha
Hobson-Peters, Jody
Kidd, Lisa
Hall, Roy A
Petrovsky, Nikolai
Safety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foals
title Safety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foals
title_full Safety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foals
title_fullStr Safety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foals
title_full_unstemmed Safety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foals
title_short Safety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foals
title_sort safety and immunogenicity of a delta inulin-adjuvanted inactivated japanese encephalitis virus vaccine in pregnant mares and foals
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268807/
https://www.ncbi.nlm.nih.gov/pubmed/25516480
http://dx.doi.org/10.1186/s13567-014-0130-7
work_keys_str_mv AT bielefeldtohmannhelle safetyandimmunogenicityofadeltainulinadjuvantedinactivatedjapaneseencephalitisvirusvaccineinpregnantmaresandfoals
AT prownataliea safetyandimmunogenicityofadeltainulinadjuvantedinactivatedjapaneseencephalitisvirusvaccineinpregnantmaresandfoals
AT wangwenqi safetyandimmunogenicityofadeltainulinadjuvantedinactivatedjapaneseencephalitisvirusvaccineinpregnantmaresandfoals
AT tancindyse safetyandimmunogenicityofadeltainulinadjuvantedinactivatedjapaneseencephalitisvirusvaccineinpregnantmaresandfoals
AT coylemitchell safetyandimmunogenicityofadeltainulinadjuvantedinactivatedjapaneseencephalitisvirusvaccineinpregnantmaresandfoals
AT doumaalysha safetyandimmunogenicityofadeltainulinadjuvantedinactivatedjapaneseencephalitisvirusvaccineinpregnantmaresandfoals
AT hobsonpetersjody safetyandimmunogenicityofadeltainulinadjuvantedinactivatedjapaneseencephalitisvirusvaccineinpregnantmaresandfoals
AT kiddlisa safetyandimmunogenicityofadeltainulinadjuvantedinactivatedjapaneseencephalitisvirusvaccineinpregnantmaresandfoals
AT hallroya safetyandimmunogenicityofadeltainulinadjuvantedinactivatedjapaneseencephalitisvirusvaccineinpregnantmaresandfoals
AT petrovskynikolai safetyandimmunogenicityofadeltainulinadjuvantedinactivatedjapaneseencephalitisvirusvaccineinpregnantmaresandfoals